Interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptor inhibit IL-1-induced glycosaminoglycan production in cultured human orbital fibroblasts from patients with Graves' ophthalmopathy

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 2, 1996, Pages 449-452

  Tan, Gerry H ^a   Dutton, Charyl M ^a   Bahn, Rebecca S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSAMINOGLYCAN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 1;

ARTICLE; AUTOIMMUNITY; COMPETITIVE INHIBITION; EYE DISEASE; FIBROBLAST; GLYCOPROTEIN SYNTHESIS; GRAVES DISEASE; GROWTH INHIBITION; HISTOLOGY; HORMONAL REGULATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; PRIORITY JOURNAL;

CELLS, CULTURED; EYE DISEASES; FIBROBLASTS; GLYCOSAMINOGLYCANS; GRAVES DISEASE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-1; SIALOGLYCOPROTEINS; TRITIUM;

EID: 0030021924     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.2.449     Document Type: Article

References (30)

1. Campbell RJ. 1984 Pathology of Graves' ophthalmopathy. In: Gorman CA, Waller RA, Dyer JA, eds. The eye and orbit in thyroid disease. New York: Raven Press; 25-31.
2. Heufelder AE, Bahn RS. 1993 Detection and localization of cytokine immunoreactivity in retroocular connective tissue in Graves' ophthalmopathy. Eur J Clin Invest. 23:10-17.
3. Korducki JM, Loftus SJ, Bahn RS. 1992 Stimulation of glycosaminoglycan production in cultured human retroocular fibroblasts. Invest Ophthalmol Vis Sci. 33:2037-2042.
4. Smith TJ, Bahn RS, Gorman CA, Cheavens M. 1991 Stimulation of glycosaminoglycan accumulation by interferon gamma in cultured human retroocular fibroblasts. J Clin Endocrinol Metab. 72:1169-1171.
5. Imai Y, Odajima R, Inoue Y, Shishiba Y. 1992 Effect of growth factors on hyaluronan and proteoglycan synthesis by retroocular tissue fibroblasts of Graves' ophthalmopathy in culture. Acta Endocrinol (Copenh). 126:541-552.
6. Bahn RS, Heufelder AE. 1993 Pathogenesis of Graves' ophthalmopathy. N Engl J Med. 329:1468-1475.
7. Bahn RS, Gorman CA, Woloschak GE, David CS, Johnson PM, Johnson CM. 1987 Human retroocular fibroblasts in vitro: a model for study of Graves' ophthalmopathy. J Clin Endocrinol Metab. 65:665-670.
8. Smith TJ, Horwitz A, Refetoff S. 1981 The effect of thyroid hormone on glycosaminoglycan accumulation in human skin fibroblasts. Endocrinology. 108:2397-2399.
9. Seckinger P, Dayer JM. 1987 Interleukin-1 inhibitors. Ann Inst Pasteur Immunol. 138:486-488.
10. Seckinger P, Lowenthal JW, Williamson K, Dayer JM, MacDonald HR. 1987 A urine inhibitor of interleukin-1 activity that blocks ligand binding. J Immunol. 139:1546-1549.
11. Arend WP, Joslin FG, Massoni RJ. 1985 Effects of immune complexes on production by human monocytes of interleukin-1 or an interleukin-1 inhibitor. J Immunol. 134:3868-3875.
12. Dinarello CA. 1991 Interleukin-1 and interleukin-1 antagonism. Blood. 77: 1627-1652.
13. 2 and collagenase production by fibroblasts and synovial cells is regulated by urine derived human interleukin-1 and inhibitor(s). J Clin Invest. 78:1120-1124.
14. Hannun CH, Wilcox CJ, Arend WP, et al. 1990 Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature. 343:336-340.
15. Blakemore A, Watson P, Weetman A, Duff G. 1995 Association of Graves' disease with an allele of the interleukin-1 receptor antagonist gene. J Clin Endocrinol Metab. 80:111-115.
16. Seckinger P, Yaron I, Meyer F, Dayer J. 1990 Modulation of the effects of interleukin-1 on glycosaminoglycan synthesis by the urine-derived interleukin-1 inhibitor but not by interleukin-6. Arthritis Rheum. 33:1807-1814.
17. Granowitz E, Porat R, Mier J, et al. 1992 Pharmacokinetics, safety, and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine. 4:353-360.
18. Granowitz E, Porat R, Mier J, et al. 1993 Hematologic and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low dose endotoxemia in healthy humans. Blood. 82:2985-2990.
19. Antin J, Weinstein H, Guinan E, et al. 1994 Recombinant human interleukin-1 receptor antagonist in the treatment of steroid resistant graft-versus-host disease. Blood. 84:1342-1348.
20. Dinarello C. 1994 Interleukin-1. Adv Pharmacol. 25:21-51.
21. Dinarello C, Thompson R. 1991 Blocking IL-1: interleukin-1 receptor antagonist in vivo and in vitro. Immunol Today. 12:404-410.
22. Fischer C, Dhainaut J, Opal S, et al. 1994 Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA. 271:1836-1843.
23. Giri J, Newton R, Horuk R. 1990 Identification of soluble interleukin-1 binding protein in cell-free supernatants. Evidence for soluble interleukin-1 receptor. J Biol Chem. 265:17416-17419.
24. Symons J, Eastgate J, Duff G. 1991 Purification and characterization of a novel soluble receptor for interleukin 1. J Exp Med. 174:1251-1254.
25. Jacobs C, Baker P, Roux E, et al. 1991 Experimental autoimmune encephalomyelitis is exacerbated by IL-1 alpha and suppressed by soluble IL-1 receptor. J Immunol. 146:2983-2989.
26. Dinarello C, Wolff S. 1993 The role of interleukin-1 in disease. N Engl J Med. 328:106-113.
27. Dinarello C, Gelfand J, Wolff S. 1993 Anticytokine strategies in the treatment of systemic inflammatory response syndrome. JAMA. 269:1829-1835.
28. Mullarkey M, Leiferman K, Peters M, et al. 1994 Human cutaneous allergic late-phase response is inhibited by soluble IL-1 receptor. J Immunol. 152:2033-2041.
29. Van Zee K, Coyle S, Calvano S, et.al. 1995 Influence of IL-1 receptor blockade on the human response to endotoxemia. J Immunol. 154:1499-507.
30. Evans C, Robbins P. 1994 The interleukin-1 receptor antagonist and its delivery by gene transfer. Receptor. 4:9-15.